Document Detail

Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
MedLine Citation:
PMID:  3312369     Owner:  NLM     Status:  MEDLINE    
Anisoylated plasminogen streptokinase activator complex (APSAC) was developed as a second generation thrombolytic agent in an attempt to overcome some of the limitations to the intravenous application of streptokinase for coronary artery thrombolysis. Temporary protection of the active site on the plasminogen molecule by acylation allows APSAC to be given by rapid injection, confers semiselectivity for clot (at lower doses) and prolonged fibrinolytic action. These properties may simplify intravenous administration, improve coronary reperfusion response and reduce reocclusion potential. Clinical trials with APSAC, still ongoing, allow the following tentative conclusions: the efficacy of intravenous APSAC appears to be equivalent to that of intracoronary streptokinase, when given within 4 hours of the onset of symptoms of myocardial infarction, and superior to that of intravenous streptokinase, but it is easier to administer. Early APSAC therapy leads to reperfusion rates of 60 to 65% and patency rates of 70 to 80%. Early reocclusion rates (within 24 hours) appear to be as low as or lower than those obtained with other agents. Bleeding complications and allergic manifestations after APSAC are acceptably low and comparable with those of equivalent doses of streptokinase. The potential for mortality benefit after APSAC appears to be high and is undergoing additional study. Thus, APSAC therapy, which can be given by simple injection over 2 to 5 minutes, appears promising as a future first line approach to reperfusion therapy in acute myocardial infarction.
J L Anderson
Related Documents :
2283199 - Pulmonary hemorrhage following intravenous streptokinase for acute myocardial infarction.
8038019 - Streptokinase neutralisation titres up to 866 days after intravenous streptokinase for ...
1791089 - Anti-streptokinase levels in indian patients.
2140889 - Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic th...
10761189 - Magnesium and calcium concentration in the abdominal aorta of patients deceased by isch...
21444059 - Implantation of a berlin heart ventricular assist device.
22327289 - Pulmonary hypertension and right heart failure in heart failure with preserved left ven...
8900339 - Pharmacologic therapies after myocardial infarction.
18159109 - Local release of catecholamines from the hearts of patients with tako-tsubo-like left v...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  10     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  1987 Nov 
Date Detail:
Created Date:  1987-12-04     Completed Date:  1987-12-04     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  22B-27B     Citation Subset:  AIM; IM    
University of Utah Hospital, Salt Lake City.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Drug Evaluation, Preclinical
Fibrinolysis / drug effects
Fibrinolytic Agents / adverse effects,  pharmacology,  therapeutic use*
Myocardial Infarction / drug therapy,  mortality
Plasminogen / adverse effects,  pharmacology,  therapeutic use*
Streptokinase / adverse effects,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-91-6/Plasminogen; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic implications of an early peak in plasma MB creatine kinase in patients with acute myocard...
Next Document:  Streptokinase for the treatment of acute myocardial infarction: a brief review of randomized trials.